James Larkin
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.2%
- Immunotherapy and Immune Responses
Papers in
- Oncology 279
- Cancer Immunotherapy and Biomarkers 188
- CAR-T cell therapy research 107
- Cutaneous Melanoma Detection and Management 53
-
- Melanoma and MAPK Pathways 156
- Renal and related cancers 57
- Co-authors
- Caroline Robert (62 shared papers)Georgina V. Long (67 shared papers)Martin Gore (73 shared papers)Matteo S. Carlino (29 shared papers)Lavinia Spain (29 shared papers)John B.A.G. Haanen (36 shared papers)Solange Peters (4 shared papers)Charles Swanton (22 shared papers)
- Journals
- Journal of Clinical Oncology (141 papers)Annals of Oncology (65 papers)The Astrophysical Journal (26 papers)European Journal of Cancer (24 papers)The Lancet Oncology (17 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
James Larkin
631 papers receiving 32.9k citations
James Larkin's Hit Papers
Peers
Comparison fields: 5 of 190
- Oncology 16.4k
- Immunology 5.1k
- Instrumentation 858
- Cancer Research 3.1k
- Pulmonary and Respiratory Medicine 6.3k
Countries citing papers authored by James Larkin
This map shows the geographic impact of James Larkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Larkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Larkin more than expected).
Fields of papers citing papers by James Larkin
This network shows the impact of papers produced by James Larkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Larkin. The network helps show where James Larkin may publish in the future.
Co-authors
The 25 scholars most cited alongside James Larkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 666 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Renal cell carcinoma Hit paper breakdown → | 2017 | 1869 |
| 2 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1757 |
| 3 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1506 |
| 4 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 5 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1033 |
| 6 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 911 |
| 7 | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma Hit paper breakdown → | 2017 | 883 |
| 8 | Immune checkpoint inhibitors in melanoma Hit paper breakdown → | 2021 | 836 |
| 9 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 788 |
| 10 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 726 |
| 11 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 696 |
| 12 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis Hit paper breakdown → | 2017 | 676 |
| 13 | Management of toxicities of immune checkpoint inhibitors Hit paper breakdown → | 2016 | 672 |
| 14 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 649 |
| 15 | Design and development of NIRSPEC: a near-infrared echelle spectrograph for the Keck II telescope Hit paper breakdown → | 1998 | 452 |
| 16 | Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling Hit paper breakdown → | 2015 | 427 |
| 17 | The First Measurement of Spectral Lines in a Short-Period Star Bound to the Galaxy’s Central Black Hole: A Paradox of Youth Hit paper breakdown → | 2003 | 425 |
| 18 | Immune checkpoint inhibitors and cardiovascular toxicity Hit paper breakdown → | 2018 | 400 |
| 19 | DETECTION AND CHARACTERIZATION OF EXOPLANETS AND DISKS USING PROJECTIONS ON KARHUNEN-LOÈVE EIGENIMAGES Hit paper breakdown → | 2012 | 336 |
| 20 | 2011 | 317 |
About James Larkin
James Larkin is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Astronomy and Astrophysics, having authored 666 papers that have together received 33.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (188 papers), Melanoma and MAPK Pathways (156 papers), Renal cell carcinoma treatment (141 papers), CAR-T cell therapy research (107 papers), Cancer Genomics and Diagnostics (81 papers), Renal and related cancers (57 papers), Cutaneous Melanoma Detection and Management (53 papers) and Astronomy and Astrophysical Research (52 papers). The work is most often cited by research in Oncology (16.4k citations), Immunology (5.1k citations), Instrumentation (858 citations), Cancer Research (3.1k citations) and Pulmonary and Respiratory Medicine (6.3k citations). James Larkin has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Caroline Robert, Georgina V. Long, Martin Gore, Matteo S. Carlino, Lavinia Spain, John B.A.G. Haanen, Solange Peters, Charles Swanton, Karin Jordan and Franck Carbonnel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Astrophysical Journal, European Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.